dexamethasone - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 1.19 [0.38, 3.72]< 10%1 study (1/-)38.6 %some concernnot evaluable moderatecrucial-
deaths 0.85 [0.77, 0.94]< 10%4 studies (4/-)99.9 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.66 [0.43, 1.02]< 10%1 study (1/-)96.9 %some concernnot evaluable moderateimportant-
death or ventilation 0.92 [0.84, 1.01]< 10%1 study (1/-)96.2 %some concernnot evaluable moderateimportant-
hospital discharge 1.10 [1.03, 1.17]> 10%1 study (1/-)99.8 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.79 [0.63, 0.99]< 11%2 studies (2/-)97.8 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 4.89 [1.15, 20.79]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-

safety endpoints 00

serious adverse events 0.53 [0.17, 1.62]< 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.